



PATENT
ATTORNEY DOCKET NO. 040894-7204

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)	
)	
Inventors: Yoko MATSUZAWA et al..)	Group Art Unit: 1654
)	
Application No. 10/530,198)	Examiner: Audet, M.A.
)	
Filed: April 4, 2005)	
)	
For: FINE SPHERICAL PARTICLES WITH)	
SATISFACTORY MOLECULAR)	
ORIENTATION, SPHERICAL MICRO-)	
CAPSULES COMPRISING THE SAME,)	
AND PROCESSES FOR PRODUCING)	
THESE)	

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner of Patents and Trademarks
U.S. Patent and Trademark Office
Customer Window
Randolph Building
401 Dulany Street
Alexandria, VA 22314

Sir:

Applicants bring to the attention of the Examiner the document listed on the attached Supplemental PTO-1449. A copy of the document is also attached for the Examiner's convenience.

Applicants respectfully request that the Examiner consider the listed document and evidence that consideration of relevant portions thereof by making appropriate notations on the attached form.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." Applicants reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed

05/05/2006 MBEYENE1 00000001 500310 10530198
01 FC:1806 180.00 DA


documents, should one or more of the documents be applied against the claims of the present application.

This Supplemental Information Disclosure Statement is filed under 37 C.F.R. §1.97(c) before the mailing of the final action under § 1.113. In accordance with 37 C.F.R. §1.97(e)(2), a fee of \$180.00 under 37 C.F.R. § 1.17(p) is due for this submission. Please charge this and any other fee the U.S. Patent and Trademark Office deems is required to Morgan, Lewis & Bockius LLP Deposit Account No. 50-0310.

Except for issue fees payable under 37 C.F.R. §1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account No. 50-0310. This paragraph is intended to be a CONSTRUCTIVE PETITION FOR EXTENSION OF TIME in accordance with 37 C.F.R. §1.136(a)(3).

Respectfully submitted,

MORGAN, LEWIS & BOCKIUS LLP

By: 
Mark J. Sullivan
Reg. No. 54,478

Dated: May 3, 2006

Customer No. 09629
MORGAN, LEWIS & BOCKIUS LLP
1800 M Street, N.W.
Washington, D.C. 20036
Tel: (202) 467-7000
Fax: (202) 467-7176

FORM PTO-1449 (modified)
To: U.S. Department of Commerce
(PW FORM PAT-1449)
Patent and Trademark Office



Atty. Dkt. No.	M#	Client Ref.
	040894-7204-US	K26-174449C/KYO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Applicant: Yoko MATSUZAWA et al.

Appln. No.: 10/530,198

Filing Date: April 4, 2005

Date: May 3, 2006

Page 1 of 1

Examiner: Audet, M.A. Group Art Unit: 1654

U.S. PATENT DOCUMENTS

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
	AR					
	BR					
	CR					
	DR					
	ER					
	FR					
	GR					
	HR					
	IR					

FOREIGN PATENT DOCUMENTS

	Document Number	Date MM/YYYY	Country	Inventor Name	English Abstract		Translation Readily Available	
					Enclosed	No	Enclose	No
	JR							
	KR							
	LR							
	MR							
	NR							
	OR							
	PR							
	QR							
	RR							

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

SR	Bergeron et al., "An Investigation of the Impact of Molecular Geometry upon Microcapsule Self-Assembly", J. Am. Chem. Soc., 117(25):6658-6665, (1995)	X		
TR				
UR				
VR				
WR				
XR				

Examiner

Date Considered:

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.